https://mindmedicinelaw.com/briefing/ampa-receptor-modulation-in-depression-potential-and-challenges-20260612-12721The Psychedelic Journalen2026-06-13T22:04:22.081975+00:00AMPA Receptor Modulation in Depression: Potential and ChallengesAMPA receptor modulation, AMPAkines, rapid-acting antidepressants, glutamatergic system, synaptic plasticity, brain-derived neurotrophic factor, pharmacokinetics, therapeutic window, clinical trials, depression treatmenthttps://mindmedicinelaw.com/briefing/mushroom-bioactives-health-benefits-applications-20260611-12672The Psychedelic Journalen2026-06-13T22:04:29.476301+00:00Mushroom Bioactives: Health Benefits & Applicationsmushroom bioactives, health benefits, neurodegenerative diseases, psychedelic research, functional foods, biomedicine, polysaccharides, antioxidant effects, pharmaceutical research, industrial technology innovationhttps://mindmedicinelaw.com/briefing/nmda-receptors-and-lhb-burst-firing-new-insights-20260611-12241The Psychedelic Journalen2026-06-12T15:06:43.198881+00:00NMDA Receptors and LHb Burst Firing: New InsightsNMDA receptors, lateral habenula, burst firing, depression treatment, ketamine, neuroscience research, antidepressants, NMDAR antagonists, neural mechanisms, clinical implicationshttps://mindmedicinelaw.com/briefing/neurobiology-of-depression-anxiety-implications-for-psychedelic-research-20260611-12242The Psychedelic Journalen2026-06-12T15:06:33.136539+00:00Neurobiology of Depression & Anxiety: Implications for Psychedelic Researchneurobiology of depression, anxiety disorders, psychedelic therapies, neurotransmitter systems, neural circuitry, precision psychiatry, neuroinflammation, genetic influences, HPA axis dysfunctionhttps://mindmedicinelaw.com/briefing/biopsychosocial-framework-for-addiction-implications-for-psychedelic-therapies-20260611-12192The Psychedelic Journalen2026-06-12T15:06:23.533065+00:00Biopsychosocial Framework for Addiction: Implications for Psychedelic Therapiesbiopsychosocial framework, addiction models, psychedelic-assisted therapy, neuroscience, public health, clinical trials, psychosocial factors, addiction treatment, multidimensional approach, emerging interventionshttps://mindmedicinelaw.com/briefing/telehealth-ketamine-for-depression-review-insights-20260611-12297The Psychedelic Journalen2026-06-12T15:05:52.199248+00:00Telehealth Ketamine for Depression: Review Insightstelehealth ketamine, depression treatment, anxiety treatment, psychedelic-assisted therapy, mental health care, systematic review, telemedicine, NMDA receptor antagonisthttps://mindmedicinelaw.com/briefing/predictive-brain-scans-for-adolescent-depression-a-new-frontier-20260610-12194The Psychedelic Journalen2026-06-12T22:04:32.402748+00:00Predictive Brain Scans for Adolescent Depression: A New Frontieradolescent depression, fMRI scan, predictive marker, mental health, early intervention, neuroimaging, brain dynamics, clinical validation, public health, mental health policyhttps://mindmedicinelaw.com/briefing/clozapine-s-impact-on-brain-structure-in-schizophrenia-20260610-12197The Psychedelic Journalen2026-06-12T22:04:24.862290+00:00Clozapine's Impact on Brain Structure in Schizophreniaclozapine, schizophrenia, brain structure, serotonergic receptors, cortical thinning, grey matter volumehttps://mindmedicinelaw.com/briefing/self-transcendence-in-moral-injury-recovery-clinical-implications-20260610-12036The Psychedelic Journalen2026-06-12T22:04:16.594536+00:00Self-Transcendence in Moral Injury Recovery: Clinical Implicationsmoral injury, self-transcendence, mindfulness, cognitive flexibility, clinical interventions, neuroscience, psychological recovery, contemplative practiceshttps://mindmedicinelaw.com/briefing/survey-reveals-variability-in-ketamine-assisted-psychotherapy-20260610-12229The Psychedelic Journalen2026-06-12T15:06:03.746754+00:00Survey Reveals Variability in Ketamine-Assisted Psychotherapyketamine-assisted psychotherapy, depression treatment, psychedelic therapy, clinical trials, psychotherapy modalities, neuroplasticity, evidence-based standardshttps://mindmedicinelaw.com/briefing/fluoxetine-and-astrocytic-camp-new-insights-in-ssri-mechanisms-20260608-12084The Psychedelic Journalen2026-06-12T22:04:52.561727+00:00Fluoxetine and Astrocytic cAMP: New Insights in SSRI Mechanismsfluoxetine, astrocytic cAMP, SSRIs, purinergic signalling, antidepressant therapy, glial cells, astrocytes, microglia, depression, neurosciencehttps://mindmedicinelaw.com/briefing/interpersonal-grounding-in-psilocybin-therapy-clinical-insights-20260608-12076The Psychedelic Journalen2026-06-12T22:04:43.982964+00:00Interpersonal Grounding in Psilocybin Therapy: Clinical Insightspsilocybin therapy, interpersonal grounding, therapist-participant relationship, psychedelic-assisted therapy, clinical trials, therapeutic models, mental health treatment, psychedelic research, therapeutic frameworks, therapy outcomeshttps://mindmedicinelaw.com/briefing/indonesia-s-drug-court-model-a-shift-in-narcotics-law-20260605-12682The Psychedelic Journalen2026-06-13T22:04:12.246913+00:00Indonesia's Drug Court Model: A Shift in Narcotics Lawindonesia drug policy, drug court model, rehabilitation over incarceration, narcotics law reform, prison overcrowding, public health outcomeshttps://mindmedicinelaw.com/briefing/psychedelics-in-palliative-care-new-evaluation-published-20260602-12301The Psychedelic Journalen2026-06-12T15:06:13.851356+00:00Psychedelics in Palliative Care: New Evaluation Publishedpsychedelics, palliative care, end-of-life care, psilocybin, MDMA, clinical trials, patient well-being, policy implications, therapeutic use, psychoactive substances